kate.chem said:The dose-response is real but shallow at the top.
Agreed, and the adaptation point cuts both ways: tachyphylaxis to gastric emptying is why tolerability improves, and it is also why people who were relying on physical fullness feel the effect fade while the appetite effect is still working.
kate.chem said:The dose-response is real but shallow at the top.
Saving this. It is the first explanation that did not require me to already understand it. Printing the relevant bit and taking it with me.
From the other side of the consultation, briefly. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsTrialNerd_Beth said:Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent…
Second this.
TrialNerd_Beth said:Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent…
Coming at TrialNerd_Beth’s question from a different direction. The pharmacokinetics explain nearly every practical question asked here. Albumin binding above 99% slows clearance enough to make weekly dosing possible; a terminal half-life near a week means four to five weeks to steady state and therefore a four-week titration interval; subcutaneous bioavailability around 89% means injection site barely matters. Those three facts answer most timing questions before they are asked.